Merck 1Q: Januvia meets CVOT goals; Keytruda ready to go in NSCLC
This article was originally published in Scrip
Executive Summary
Merck & Co saw worldwide sales fall by 8% in the first quarter of 2015 but major products met expectations – including diabetes therapy Januvia (sitagliptin), which received further positive news on 27 April when Merck reported the drug didn't increase the risk of heart problems in patients.
You may also be interested in...
Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza
Merck got a complete response letter from FDA on a cardiovascular risk-reduction claim for the DPP-4 inhibitor based on TECOS trial data. This places Januvia/Janumet behind Jardiance, which already has a CV safety label claim, and Victoza, which awaits an FDA decision on a supplemental NDA filed last October.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.